Stock 4578 OTSUKA HOLDINGS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Market Closed - Japan Exchange
Other stock markets
 07:00:00 26/04/2024 BST 		5-day change 1st Jan Change
6,370 JPY +1.56% Intraday chart for Otsuka Holdings Co., Ltd. +2.97% +20.44%
04-09 H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
03-29 Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
B+
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
B-
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B -
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
B+
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
B+
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-4.29% 4.71B
D+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4578 Stock
  4. Ratings Otsuka Holdings Co., Ltd.